Stomach infection return in liver disease patients study
Part of Digestive system, Infections clinical trials.
This study looks at why some patients with cirrhosis get a serious stomach infection called SBP more than once. It may help doctors predict and prevent repeat infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have cirrhosis (scarred liver) with fluid buildup in the belly
- You have had a first episode of SBP (stomach infection) confirmed by a high white blood cell count in the belly fluid
- You have not been diagnosed with a different type of belly infection caused by a hole or surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether simple blood tests (platelet count, sodium, and a liver score) can predict a serious infection called spontaneous bacterial peritonitis (SBP) in people with cirrhosis and fluid buildup in the belly (ascites). If successful, it could help doctors catch this infection earlier.
This study tests a new scoring system to predict a serious infection called spontaneous bacterial peritonitis (SBP) in people with liver cirrhosis and fluid buildup in the belly (ascites). It aims to help catch the infection early so treatment can start sooner.
This trial tests whether draining infected belly fluid early can help people with cirrhosis and a type of infection called SBP (spontaneous bacterial peritonitis). If you have cirrhosis and your belly fluid is infected, this study may show if early drainage improves recovery.
This study tests whether taking norfloxacin plus itopride helps prevent another episode of spontaneous bacterial peritonitis (a serious belly infection) in people with cirrhosis and fluid buildup in the abdomen. It compares that combo to norfloxacin alone to see which approach better lowers repeat infections.
This trial tests whether a lower dose of albumin works as well as the standard dose for people with cirrhosis and a type of infection called spontaneous bacterial peritonitis (SBP). It aims to see if the low dose can protect kidney function while reducing side effects and costs.
This study looks for signs that predict a bacterial infection in the belly fluid of people with liver cirrhosis. It aims to catch infection early and improve treatment for patients with ascites.
Hear when a new Spontaneous Bacterial Peritonitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.